NetworkNewsBreaks – CytoDyn Inc. (CYDY) Names Ri
Post# of 154122
(Total Views: 145)
Posted On: 01/07/2019 3:25:21 PM
NetworkNewsBreaks – CytoDyn Inc. (CYDY) Names Richard G. Pestell, M.D., Ph.D. as Board Vice Chairman, Expanding Leadership Role in Advancement of Company Initiatives
Biotechnology company CytoDyn (OTCQB: CYDY) today announced the election of its Chief Medical Officer and Director Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P. to the additional position of vice chairman of the board of directors. In this added role Pestell, an internationally renowned clinician and cancer researcher and defining force in CCR5 antagonist research, will advance and accelerate CYDY’s initiatives in seeking non-dilutive licensing opportunities in cancer and immunology.
“We are honored to have Dr. Pestell serve as our Vice Chairman,” CytoDyn President and Chief Executive Officer Nader Pourhassan stated in the news release. “He is a world renowned cancer expert who has published over 500 papers. We envision the role of our Vice Chairman to serve as an ambassador capable of delivering our message of the potential for our platform drug leronlimab (“PRO 140”) worldwide. It just makes sense to elevate Dr. Pestell to this position, as we expect future results from our program to bring our technology into the spotlight. Dr. Pestell has the credibility on the world stage to represent the technology to other drug companies, potential collaborators, licensees and key opinion leaders. We also recognize his track record of success in overseeing cancer clinical trials for more than 13 years as the Director of two NCI -designated cancer centers. His expertise using CCR5 inhibitors in preclinical studies and the relationships he built while maintaining his commitment to excellence facilitated the approval from the FDA to proceed with our cancer trial. With his broad leadership experience and CCR5 expertise, CytoDyn has strengthened the development of leronlimab as a novel therapeutic for cancer metastasis.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company CytoDyn (OTCQB: CYDY) today announced the election of its Chief Medical Officer and Director Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P. to the additional position of vice chairman of the board of directors. In this added role Pestell, an internationally renowned clinician and cancer researcher and defining force in CCR5 antagonist research, will advance and accelerate CYDY’s initiatives in seeking non-dilutive licensing opportunities in cancer and immunology.
“We are honored to have Dr. Pestell serve as our Vice Chairman,” CytoDyn President and Chief Executive Officer Nader Pourhassan stated in the news release. “He is a world renowned cancer expert who has published over 500 papers. We envision the role of our Vice Chairman to serve as an ambassador capable of delivering our message of the potential for our platform drug leronlimab (“PRO 140”) worldwide. It just makes sense to elevate Dr. Pestell to this position, as we expect future results from our program to bring our technology into the spotlight. Dr. Pestell has the credibility on the world stage to represent the technology to other drug companies, potential collaborators, licensees and key opinion leaders. We also recognize his track record of success in overseeing cancer clinical trials for more than 13 years as the Director of two NCI -designated cancer centers. His expertise using CCR5 inhibitors in preclinical studies and the relationships he built while maintaining his commitment to excellence facilitated the approval from the FDA to proceed with our cancer trial. With his broad leadership experience and CCR5 expertise, CytoDyn has strengthened the development of leronlimab as a novel therapeutic for cancer metastasis.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)